allogeneic anti-CD19 CAR T-cell therapy (University College London)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameallogeneic anti-CD19 CAR T-cell therapy (University College London)
Drug Alias NameCD19 chimeric antigen receptor immunotherapy (University College London)CD19-targeted Epstein-Barr virus-specific cytotoxic T-lymphocytes (University College London)CD19-zeta chimeric receptor-transduced donor-derived EBV-CTLs (University College London)CD19-specific EBV-CTL therapy (University College London)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEuropeUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesUniversity College London
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A